Organo-ID is developing micro human tissues derived from stem cells using advanced 3D technology to create disease models. By utilizing organoids derived from pluripotent stem cells, the company conducts tests on cancer patients' organoids, enabling the assessment of drug safety, efficacy, and response without the need for human trials.

‍